Surgical Innovations Group PLC
18 December 2006
Press Release 18 December 2006
Surgical Innovations Group plc
('Surgical' or 'the Group')
Provider of Choice for major US hospital group
Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of
innovative surgical devices, today announces that it has been approved by the
North Shore Long Island Jewish Health System ('North Shore') as an accredited
supplier of laparoscopic equipment.
Following extensive trials across all disciplines of laparoscopic surgery within
the North Shore hospital group, the Group's market-leading 'resposable' (a
mixture of both reusable and disposable items) and versatile YelloPort abdominal
access system will be supplied to operating theatres in pre-prepared equipment
trays, tailored to each type of operation.
North Shore is the USA's third-largest non-profit secular healthcare systems
group, comprising 15 hospitals, with in excess of 6,000 beds. With a US$4
billion annual operating budget and more than 38,000 employees, North Shore
services an area of 5.2 million people in New York State.
North Shore treats more than 235,000 in-patients annually and offers a full
spectrum of advanced minimally invasive procedures. There are 4.4 million
laparoscopic surgical procedures carried out each year in the US (Source:
Patient Safety and Quality Healthcare journal, May/June 2005) and the worldwide
demand for such operations is escalating with the majority of countries now
undertaking these procedures on a routine basis.
Graham Bowland, Joint Managing Director of Surgical Innovations, commented: 'We
are delighted to have been accredited by North Shore and look forward to further
opportunities to demonstrate our range of surgical instruments. We believe this
is a positive step in the growth of the Group and are confident that this
invaluable endorsement from pre-eminent surgeons at a respected hospital group
will help us gain accredited supplier status in further hospitals across the
USA.'
- Ends -
For further information:
Surgical Innovations Group plc
Graham Bowland, Managing Director Tel: +44 (0) 113 230 7597
graham.bowland@surginno.co.uk www.sigroupplc.com
Hanson Westhouse LLP
Tim Feather Tel: +44 (0) 113 246 2610
tim.feather@hansonwesthouse.com www.hansonwesthouse.com
Media enquiries:
Abchurch
Gareth Mead / Justin Heath Tel: +44 (0) 20 7398 7710
gareth.mead@abchurch-group.com www.abchurch-group.com
Notes to Editors:
Surgical Innovations Group plc specialises in the design and manufacture of
innovative devices for use in minimally invasive surgery and industrial markets.
The Group employs over 50 people and is headquartered in Leeds.
The Group's medical division is focused on strong international growth in two
specialist areas namely minimally invasive surgery, where products are used in
'keyhole' surgery which is more accurately known as laparoscopic surgery, and
products for autologous blood transfusion whereby a patient's own blood is
recycled.
The Group's industrial division utilises Surgical Innovations' core medical
device design expertise and technology in innovative engineering applications.
For more information, see www.sigroupplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.